Basis: Trailing twelve months (TTM net income over TTM revenue). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the net profit margin high or low?
The net profit margin of 0.00% is 100% below its 1-year average of 18.84%, near the low end of its 1-year range (0.00%–94.19%).
As of the fiscal period ended Tuesday, June 30, 2026. 100.00% below its 12-month average of 18.84%.
Reported quarterly profit margin; no daily interpolation. Q2 FY2026 (2026-06-30): 0.00%.
NET PROFIT MARGIN
0.00%
NET PROFIT MARGIN AVG TTM
18.84%
NET PROFIT MARGIN AVG 3Y
0.00%
NET PROFIT MARGIN AVG 5Y
0.00%
NET PROFIT MARGIN AVG 10Y
N/A
NET PROFIT MARGIN AVG 15Y
N/A
NET PROFIT MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-100.00%
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-0.26%
median of 863 covered companies
CURRENT VS SECTOR MEDIAN
+100.00%
vs the sector median at left
Faeth Therapeutics, Inc.
Market Cap
$720.96M
Net Profit Margin
0.00%
TTM Avg
18.84%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$718.03M
Net Profit Margin
-38.98%
TTM Avg
-18.01%
3Y Avg
-10.19%
5Y Avg
-2.91%
Market Cap
$716.46M
Net Profit Margin
-170055.93%
TTM Avg
-70304.07%
3Y Avg
-35619.60%
5Y Avg
-24164.90%
Market Cap
$714.71M
Net Profit Margin
5.93%
TTM Avg
9.51%
3Y Avg
5.53%
5Y Avg
9.43%
Market Cap
$730.14M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
-3758.80%
5Y Avg
-9679.73%
Market Cap
$730.93M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$698.54M
Net Profit Margin
-309.73%
TTM Avg
-283.95%
3Y Avg
-1263.35%
5Y Avg
-1016.41%
Market Cap
$697.15M
Net Profit Margin
-4619.67%
TTM Avg
-3871.87%
3Y Avg
-2595.36%
5Y Avg
-1815.29%
Market Cap
$697.03M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
| NAME | MARKET CAP | NET PROFIT MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Faeth Therapeutics, Inc. (FTH) | $720.96M | 0.00% | 18.84% | 0.00% | 0.00% |
| Cytek Biosciences, Inc. (CTKB)vs › | $718.03M | -38.98% | -18.01% | -10.19% | -2.91% |
| Avalo Therapeutics, Inc. (AVTX)vs › | $716.46M | -170055.93% | -70304.07% | -35619.60% | -24164.90% |
| Collegium Pharmaceutical, Inc. (COLL)vs › | $714.71M | 5.93% | 9.51% | 5.53% | 9.43% |
| Candel Therapeutics, Inc. (CADL)vs › | $730.14M | 0.00% | 0.00% | -3758.80% | -9679.73% |
| Achieve Life Sciences, Inc. (ACHV)vs › | $730.93M | 0.00% | 0.00% | 0.00% | 0.00% |
| Wave Life Sciences Ltd. (WVE)vs › | $698.54M | -309.73% | -283.95% | -1263.35% | -1016.41% |
| Anteris Technologies Global Corp. (AVR)vs › | $697.15M | -4619.67% | -3871.87% | -2595.36% | -1815.29% |
| Olema Pharmaceuticals, Inc. (OLMA)vs › | $697.03M | 0.00% | 0.00% | 0.00% | 0.00% |
| Design Therapeutics, Inc. (DSGN)vs › | $747.61M | 0.00% | 0.00% | 0.00% | 0.00% |
Operating Margin
0.0%
Net Profit Margin
0.0%
Net Profit Margin = Net Income / Revenue
Net profit margin is the percentage of revenue that becomes net income after all expenses, taxes, and interest.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | NET PROFIT MARGIN |
|---|---|
| 2026-06-30 | 0.00% |
| 2026-03-31 | 0.00% |
| 2025-12-31 | 0.00% |
| 2025-09-30 | 94.19% |
| 2025-06-30 | 0.00% |
| 2025-03-31 | 0.00% |
| 2024-12-31 | 0.00% |
| 2024-09-30 | 0.00% |
| 2024-06-30 | 0.00% |
| 2024-03-31 | 0.00% |
| 2023-12-31 | 0.00% |
| 2023-09-30 | 0.00% |
| 2023-06-30 | 0.00% |
| 2023-03-31 | 0.00% |
| 2022-12-31 | 0.00% |
| 2022-09-30 | 0.00% |
| 2022-06-30 | 0.00% |
| 2022-03-31 | 0.00% |
| 2021-12-31 | 0.00% |
| 2021-09-30 | 0.00% |
| 2021-06-30 | 0.00% |
| 2021-03-31 | 0.00% |
| 2020-12-31 | 0.00% |
| 2020-09-30 | 0.00% |
| 2020-06-30 | 0.00% |
| 2020-03-31 | 0.00% |
| 2019-12-31 | 0.00% |
